Modulating Metabolic Inflammation & Enhanced Brain Insulin Sensitivity to Decrease Progression of Neurodegeneration
Time: 2:30 pm
day: Clinical & Commercial Track PM
Details:
- Increasing insulin sensitivity to inhibit the inflammatory ERK signalling pathway to reduce neuroinflammation by inhibition inflammation-driven insulin resistance and major pathological inflammatory cascades
- Reviewing phase 3 data for NE3107 as an anti-inflammatory insulin sensitizer to treat patients with mild to moderate Alzheimer’s Disease
- Exploring preliminary biomarker findings for NE3107 in modulating progression of neurodegeneration
